News
FDA backs Curium's Bexlutry as 1st 'radioligand equivalent'
Curium's copycat version of Novartis GEP-NET therapy Lutathera, Bexlutry, is the first radioligand equivalent (RLE) to be approved by the FDA.
Sales & Marketing
The patient communication crisis pharma can no longer ignore
Industry's significant investments in patient engagement are only effective if patients trust the communication enough to answer in the first place.
News
Chiesi fills permanent CEO role with Flagship's Khougazian
Chiesi has named Flagship's David Khougazian as its new permanent chief executive, following the departure of Giuseppe Accogli earlier this year.
Sales & Marketing
Headcount is not a growth strategy
Deciding when, where, and how quickly to add headcount is rarely straightforward.
News
FDA to decide on Takeda's psoriasis blockbuster hope in Q1
The FDA has started a review of the marketing application for Takeda's TYK2 inhibitor zasocitinib in psoriasis, setting up a decision in mid-March.
News
Press Releases
Views & Analysis
Editor's Picks
Editor's Picks
